Dimension Therapeutics Inc (DMTX) Given Average Rating of “Hold” by Brokerages

Dimension Therapeutics Inc (NASDAQ:DMTX) has earned an average rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $4.60.

Separately, Chardan Capital reaffirmed a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, December 22nd.

Shares of Dimension Therapeutics (DMTX) opened at $5.95 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.33 and a current ratio of 2.01. Dimension Therapeutics has a 12 month low of $1.05 and a 12 month high of $6.10. The firm has a market cap of $149.06 and a P/E ratio of -2.67.

A number of large investors have recently modified their holdings of the stock. K2 Principal Fund L.P. bought a new position in Dimension Therapeutics in the third quarter worth approximately $960,000. Kassirer Asset Management Corp bought a new position in Dimension Therapeutics in the third quarter worth approximately $952,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in Dimension Therapeutics in the third quarter worth approximately $600,000. Finally, Goldman Sachs Group Inc. raised its stake in Dimension Therapeutics by 206.7% in the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after buying an additional 54,231 shares in the last quarter. 70.33% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/13/dimension-therapeutics-inc-dmtx-given-average-rating-of-hold-by-brokerages.html.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply